🇺🇸 FDA
Patent

US 7294687

Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

granted A61KA61K31/724A61K38/10

Quick answer

US patent 7294687 (Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Nov 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Nov 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/724, A61K38/10, A61K47/6951, A61K9/0019